Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.34 |
| ▸ | PDE4A | P27815 | 2/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | F13A1 | P00488 | 1/20 | 0.31 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
| ▸ | TGM1 | P22735 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | STS | P08842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29562748 | 1.00 | BUB1 (0.34) | BUB1L3MBTL1PDE4BPDE4APDE4C | |
| SCHEMBL31430132 | 0.89 | PDE4B (0.33) | BUB1L3MBTL1PDE4BPDE4APDE4C | |
| SCHEMBL29792872 | 0.89 | HSP90AA1 (0.35) | BUB1L3MBTL1PDE4BPDE4APDE4C | |
| SCHEMBL30689286 | 0.89 | PDE4B (0.33) | BUB1L3MBTL1PDE4BPDE4APDE4C | |
| SCHEMBL25900845 | 0.89 | HSP90AA1 (0.35) | BUB1L3MBTL1PDE4BPDE4APDE4C | |
| SCHEMBL29238947 | 0.89 | L3MBTL1 (0.35) | BUB1L3MBTL1PDE4BPDE4APDE4C | |
| SCHEMBL26494303 | 0.88 | BUB1 (0.39) | BUB1L3MBTL1HTR6ACLYHSP90AA1 | |
| SCHEMBL31135931 | 0.88 | BUB1 (0.39) | BUB1L3MBTL1HTR6ACLYHSP90AA1 | |
| SCHEMBL17467549 | 0.87 | PDE4B (0.32) | BUB1L3MBTL1PDE4BPDE4APDE4C | |
| SCHEMBL24835169 | 0.87 | SUV39H2 (0.37) | BUB1PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382287-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF NITROGEN-CONTAINING BRIDGE HETEROCYCLIC DERIVATIVE, AND METHOD FOR PREPARING SAME | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| EP-4650351-A1 | INHIBITOR OF COMPLEMENT FACTOR B | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-20250250267-A1 | NITROGEN-CONTAINING BRIDGED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2025-08-07 | — | — | US | disclosed |
| EP-4549435-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF NITROGEN-CONTAINING BRIDGE HETEROCYCLIC DERIVATIVE, AND METHOD FOR PREPARING SAME | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-05-07 | — | — | EP | disclosed |
| US-20250115572-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS PHARMA AG (CH) | 2025-04-10 | — | — | US | disclosed |
| WO-2024149261-A1 | INHIBITOR OF COMPLEMENT FACTOR B | 南京正大天晴制药有限公司 | 2024-07-18 | — | — | WO | disclosed |
| US-20240217953-A1 | BICYCLIC SUBSTITUTED AROMATIC CARBOXYLIC ACID COMPOUNDS | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217953-A1 | BICYCLIC SUBSTITUTED AROMATIC CARBOXYLIC ACID COMPOUNDS | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| WO-2024114677-A1 | PREPARATION, APPLICATION AND USE OF BENZOSPIROINDOLE COMPOUNDS | 上海济煜医药科技有限公司 | 2024-06-06 | — | — | WO | disclosed |
| US-20240182503-A1 | MACROCYCLE COMPLEMENT FACTOR B INHIBITORS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-20180009795-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | NOVARTIS AG (CH) | 2018-01-11 | — | — | US | disclosed |
| EP-3022192-B1 | PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS | NOVARTIS AG (CH) | 2017-10-11 | — | — | EP | disclosed |
| EP-3022192-B1 | PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS | NOVARTIS AG (CH) | 2017-10-11 | — | — | EP | disclosed |
| US-9682968-B2 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-9682968-B2 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-9682968-B2 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-20160152605-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | NOVARTIS AG (CH) | 2016-06-02 | — | — | US | disclosed |
| US-20160152605-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | NOVARTIS AG (CH) | 2016-06-02 | — | — | US | disclosed |
| US-20160152605-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | NOVARTIS AG (CH) | 2016-06-02 | — | — | US | disclosed |
| WO-2015009616-A1 | PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250267-A1 | NITROGEN-CONTAINING BRIDGED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | CFB, F11, CFH | BUB1 2136/4885L3MBTL1 4584/4885PDE4B 2801/4885 |
| US-20160152605-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | CFB, TFPI, TFPI2 | BUB1 2883/4885L3MBTL1 4864/4885PDE4B 758/4885 |
| US-20250115572-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | CFB, C1QBP, CFH | BUB1 2710/4885L3MBTL1 4820/4885PDE4B 1645/4885 |
| US-20240182503-A1 | MACROCYCLE COMPLEMENT FACTOR B INHIBITORS | CFB, CFH, C9 | BUB1 1576/4885L3MBTL1 2589/4885PDE4B 2252/4885 |
| US-20250382287-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF NITROGEN-CONTAINING BRIDGE HETEROCYCLIC DERIVATIVE, AND METHOD FOR PREPARING SAME | SLC38A7, SLC28A1, ATIC | BUB1 832/4885L3MBTL1 4687/4885PDE4B 2877/4885 |
| US-20180009795-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | CFB, C5, TFPI | BUB1 2640/4885L3MBTL1 4869/4885PDE4B 786/4885 |
| US-20240217953-A1 | BICYCLIC SUBSTITUTED AROMATIC CARBOXYLIC ACID COMPOUNDS | C9, CFB, C5 | BUB1 1982/4885L3MBTL1 4569/4885PDE4B 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.